| |
| | Conference on Ibogaine, NYU School of Medicine, Nov. 5-6, 1999. |
 | | Ibogaine does not appear to be a conventional dopamine or opioid agonist or antagonist, or an amine re-uptake inhibitor and is not a substitution therapy, such as methadone (Glick and Maisonneuve, 1998; Popik et al., 1995; Popik and Glick, 1996; Popik and Skolnick, 1999). |
 | | Ibogaine effects are relatively more evident in animals with prior exposure to amphetamine (Blackburn and Szumlinski, 1997) or morphine (Pearl et al., 1995; Pearl et al., 1996), which is also consistent with an effect of ibogaine on neuroadaptations acquired from drug exposure. |
 | | Ibogaine is particularly unattractive, because its mechanism of action is complex and incompletely understood, and its patent is close to expiration. |
| www.med.nyu.edu /psych/ibogaineconf/objectives.html (3863 words) |
|